3 tracked superinvestors hold ROIVANT SCIENCES LTD (ROIV), worth $974M combined, led by Steve Wymer. Smart money is holding ROIV as of the latest 13F filings.
Current price
$34.93
+177.9%
1Y
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions…
Market cap
$19.9B
P/E
-23.79
Div yield
0.0%
Revenue YoY
-71.6%
Analyst target
$40
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
3
tracked 13F / N-PORT funds
Combined value
$974M
disclosed long exposure
Tier-1 conviction
2
concentrated holders
Net this quarter
0
1 buying · 1 selling
Smart money is holding ROIV steady this quarter — buys and sells are balanced. 1 opened a brand-new position.
ROIVANT SCIENCES LTD (ROIV) is held by 3 tracked funds worth $974M combined, 2 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to Steve Wymer at 0.7% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
This quarter 1 fund opened a brand-new position (Steve Wymer), with 0 adding and 1 trimming — a net accumulation signal.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| New buy | 0.7% | $675M | |
| Trimmed | 0.6% | $222M | |
| Held | 2.1% | $76M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
5 insiders filed SEC Form 144 for $91M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Meghan Fitzgerald | Director | 20,000 | $699K | 2026-09-08 |
| Venker Eric | Officer | 200,000 | $7M | 2026-08-28 |
| Mayukh Sukhatme | Officer & Director | 144,756 | $5M | 2026-08-21 |
| Mayukh Sukhatme | Officer & Director | 17,519 | $653K | 2026-08-20 |
| Mayukh Sukhatme | Officer & Director | 172,899 | $6M | 2026-08-19 |
| Mayukh Sukhatme | Officer & Director | 136,942 | $5M | 2026-08-18 |
| Mayukh Sukhatme | Officer & Director | 284,707 | $10M | 2026-08-17 |
| Venker Eric | Officer | 200,000 | $7M | 2026-07-27 |
Which superinvestors own ROIV?
3 tracked funds hold ROIVANT SCIENCES LTD (ROIV), the largest being Steve Wymer (Fidelity Growth Company) at 0.7% of its 13F portfolio. 2 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling ROIV?
In the most recent 13F quarter, 1 tracked fund added or opened ROIV and 1 trimmed it, including 1 brand-new position.
How much ROIV do tracked funds hold?
Combined disclosed long exposure to ROIV across tracked superinvestors is $974M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.